Condition: Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Sponsor: Aptamer Sciences, Inc.
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
This description comes directly from the study's public registry record.
Aptamer Sciences Inc. · +82-70-5067-4275 · kjkim@aptsci.com
Always discuss trial participation with your own doctor first.
| National Cancer Center, Korea | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
| CHA Bundang Medical Center | Seongnam, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06687941